However, pre- and co-treatment with tempol significantly (p < 0.01) upregulated the mRNA expression of NGF in comparison with the CIS-treated group and still revealed a significant difference from the control and TEM groups (Figure 5A). This evidence concerns the gene NGF and in situ carcinoma.